Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized phase 1, open-labeled clinical study, 1-arm, single center, to
observe efficacy and safety of chemotherapy plus PD-L1 antibody Toripalimab every 21 days for
2 cycles as induction regimen in locoregionally-advanced laryngo-hypopharyngeal squamous cell
cancer patients.